Program
linsitinib
Also written as “OSI-906” and “Linsitinib”.
Its studies are mostly in Graves Ophthalmopathy · Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Adrenocortical Carcinoma · Carcinoma, Hepatocellular, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 100 open or running | phase 3since Jun 17, 2009 | Aug 7, 2007 | none ahead |
| Sling Therapeutics | 32 open or running | phase 3since Mar 2, 2022 | Mar 2, 2022 | Jun 30, 2028phase 3 · NCT07753603 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 7, 2007First studies: 2 phase 1 studiesNew to Astellas PharmaAstellas Pharma · NCT00514306, NCT00514007
- Aug 19, 2008Phase 1 study in Pancreatic NeoplasmsAstellas Pharma · NCT00739453 · 95 enrolled · United States, United Kingdom
- Apr 6, 2009Phase 2 study in Ovarian NeoplasmsAstellas Pharma · NCT00889382 · 152 enrolled · United States, Australia, Canada and more
- Jun 17, 2009Phase 3 study in Adrenocortical CarcinomaAstellas Pharma · NCT00924989 · 139 enrolled · United States, Australia, Canada and more
- Apr 8, 2010Phase 2 study in Carcinoma, HepatocellularAstellas Pharma · NCT01101906 · 23 enrolled · United States, Belgium, France and more
- Aug 19, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungAstellas Pharma · NCT01186861 · 205 enrolled · United States, Brazil, Canada and more
- Oct 5, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungAstellas Pharma · NCT01221077 · 88 enrolled · United States, Canada, Hong Kong and more
- Feb 7, 2012Phase 1 study in NeoplasmsAstellas Pharma · NCT01529684 · 5 enrolled · United States
- Feb 5, 2014Phase 2 study in Advanced Solid TumorsAstellas Pharma · NCT02057380 · 13 enrolled · United States, Brazil, Czechia and more
- Mar 2, 2022Sling Therapeutics's first study: phase 3 study in Graves OphthalmopathyNew to Sling TherapeuticsSling Therapeutics · NCT05276063 · 90 enrolled · United States, Canada, Italy and more
- Oct 16, 2023Phase 3 study in Graves OphthalmopathySling Therapeutics · NCT06112340 · 75 planned · United States
- Aug 3, 2026Phase 3 study in Graves OphthalmopathySling Therapeutics · NCT07753603 · 130 planned · United States
Ahead
- Jun 30, 2028Primary completion: phase 3 study in Graves OphthalmopathySling Therapeutics · NCT07753603
TargetBeta
“An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) ”NCIt, by rule
“Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07753603Graves Ophthalmopathy · United States | 3 | Recruiting | Sling Therapeutics | Jun 30, 2028 | 130 |
| NCT06112340Graves Ophthalmopathy · United States | 3 | Recruiting | Sling Therapeutics | Jun 2026 | 75 |
| NCT05276063Graves Ophthalmopathy · United States, Canada, Italy and more | 3 | Completed | Sling Therapeutics | Oct 15, 2024 | 90 |
| NCT02057380Advanced Solid Tumors · United States, Brazil, Czechia and more | 2 | Completed | Astellas Pharma | Oct 14, 2016 | 13 |
| NCT01529684Neoplasms · United States | 1 | Completed | Astellas Pharma | Dec 8, 2012 | 5 |
| NCT01221077Carcinoma, Non-Small-Cell Lung · United States, Canada, Hong Kong and more | 2 | Completed | Astellas Pharma | Mar 1, 2013 | 88 |
| NCT01186861Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more | 2 | Completed | Astellas Pharma | Jul 1, 2013 | 205 |
| NCT01101906Carcinoma, Hepatocellular · United States, Belgium, France and more | 2 | Terminated | Astellas Pharma | Nov 4, 2011 | 23 |
| NCT00924989Adrenocortical Carcinoma · United States, Australia, Canada and more | 3 | Completed | Astellas Pharma | Jul 11, 2012 | 139 |
| NCT00889382Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Completed | Astellas Pharma | Aug 1, 2014 | 152 |
| NCT00739453Pancreatic Neoplasms · United States, United Kingdom | 1 | Completed | Astellas Pharma | Mar 3, 2012 | 95 |
| NCT00514306Ovarian Neoplasms · United States, United Kingdom | 1 | Completed | Astellas Pharma | Sep 20, 2010 | 79 |
| NCT00514007Colorectal Neoplasms · United States, United Kingdom | 1 | Completed | Astellas Pharma | Mar 19, 2012 | 95 |
How it is read
Names in the registry
- “OSI-906”, 9 entries
- “linsitinib”, 3 entries
- “Linsitinib”, 1 entry
Conditions, from the studies’ own filings
- Graves Ophthalmopathy, 3 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Ovarian Neoplasms, 2 studies
- Adrenocortical Carcinoma, 1 study
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.